Medtronic plc
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Geoffrey Straub Martha
- Full Time Employees
- 95,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Building Two, Parkmore Business Park West Galway United States of America 2
- IPO Date
- May 2, 1973
- CIK
- 0001613103
- Website
- medtronic.com
- Similar Companies
- Business
- Medtronic plc (NYSE: MDT) develops, manufactures, and markets a wide range of medical devices and therapies for the treatment of chronic diseases worldwide. The company offers products across four main segments: cardiovascular (including pacemakers, defibrillators, heart valves, and coronary stents under brands such as Evera, Protecta, and CoreValve); medical surgical (featuring surgical navigation systems, endoscopic tools, and stapling devices like Hugo RAS and Valiant NaviCore); neuroscience (encompassing spinal cord stimulators, deep brain stimulation systems, and intrathecal drug delivery pumps such as Incepta and SynchroMed II); and diabetes (primarily continuous glucose monitoring systems, insulin pumps, and related software through the MiniMed and Guardian brands). Medtronic provides services including patient management software, remote monitoring platforms, and clinical decision support tools to healthcare providers, hospitals, clinics, and patients globally. Founded in 1949 and headquartered in Dublin, Ireland, with principal executive offices in Minneapolis, Minnesota, USA, Medtronic operates in more than 150 countries, serving markets in North America, Europe, Asia-Pacific, Latin America, and the Middle East through direct sales forces, distributors, and subsidiaries. The company targets physicians, hospitals, ambulatory surgery centers, and home care settings, with a focus on minimally invasive therapies and digital health solutions. Key subsidiaries include Covidien (acquired in 2015 for surgical and patient monitoring products) and Intersect ENT (recently integrated for sinus implants). In the past 1-2 years, Medtronic has pursued strategic expansions including the FDA approval and U.S. launch of the Hugo robotic-assisted surgery (RAS) system in 2024 for soft tissue indications, building on its European CE Mark; a multi-year collaboration with NVIDIA announced in 2024 to advance AI-enabled therapies using Medtronic's Gigamon data platform; and the acquisition of Mazor Robotics in 2018 followed by ongoing enhancements to its spinal robotics portfolio with the Mazor X Stealth Edition. The company completed a $4.1 billion acquisition of Covidien assets integration and reported expansions in diabetes care via the Simplera Sync sensor FDA clearance in 2024. Medtronic also announced organizational realignments in 2025 to streamline its four operating units amid portfolio optimization efforts.
Got $2,500? 1 Unstoppable Medical Juggernaut to Buy Hand Over Fist and Hold for the Next 20 Years
Dividend Announcements: May 30-June 5, 2026
Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
Medtronic Bets on Ablation, Robotics, and Hypertension
Is Medtronic Stock a Buy at 14x Forward Earnings?
5 Best Dividend Stocks to Own in Case the AI Trade Ends
As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play
Medtronic: A Dividend Aristocrat At A Steal Now
Why Medtronic Stock May Have Just Become the Best Buy in the Entire Healthcare Sector
Can Medtronic Finally Challenge Intuitive Surgical's Robotic Surgical Systems Dominance?
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
Is Medtronic (MDT) a Buy as Wall Street Analysts Look Optimistic?
3 High-Yielding Dividend Stocks That Just Raised Their Payouts
Wall Street May Be Mispricing Medtronic, Analyst Says
Medtronic Bottoms, Healthy Rebound Ahead
MDT Q4 Earnings Call Points to Another Year of Growth
Medtronic plc (MDT) Q4 2026 Earnings Call Transcript
Medtronic PLC (MDT) Q4 2026 Earnings Call Highlights: Record Revenue Growth and Strategic Innovations
Why Medtronic Stock Popped Today
Medtronic (MDT) Posts Strong Q4 Results with Promising FY27 Growth Outlook